VERTEX PHARMACEUTICALS INC / MA Repayments of Lines of Credit
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Repayments of Lines of Credit of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLinesOfCredit · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for the quarter ending 2018-12-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for the quarter ending 2018-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for the quarter ending 2018-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for fiscal 2019 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for fiscal 2017 was $300.00M.
- VERTEX PHARMACEUTICALS INC / MA repayments of lines of credit for fiscal 2016 was $0.00.
| Period end | Repayments of Lines of Credit 1 month | Repayments of Lines of Credit 3 month | Repayments of Lines of Credit 6 month | Repayments of Lines of Credit 9 month | Repayments of Lines of Credit 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2018-10-25 | $0.00 10-Q · filed 2018-10-25 | $0.00 derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $0.00 10-Q · filed 2018-07-26 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $0.00 derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-03-31 | $0.00 10-Q · filed 2018-04-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $0.00 derived: sum of 4 quarters · filed 2020-02-13 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $300.00M 10-K · filed 2020-02-13 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $0.00 derived: sum of 2 quarters · filed 2018-10-25 | $300.00M 10-Q · filed 2018-10-25 | $300.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-26 | $300.00M 10-Q · filed 2018-07-26 | $300.00M derived: sum of 3 quarters · filed 2019-02-13 | $300.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-03-31 | $300.00M 10-Q · filed 2018-04-27 | $300.00M derived: sum of 2 quarters · filed 2019-02-13 | $300.00M derived: sum of 3 quarters · filed 2019-02-13 | $300.00M derived: sum of 4 quarters · filed 2019-02-13 | |
| 2017-02-28 | $300.00M 10-Q · filed 2017-10-30 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $0.00 derived: sum of 2 quarters · filed 2019-02-13 | $0.00 derived: sum of 3 quarters · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | $0.00 derived: sum of 2 quarters · filed 2017-10-30 | $0.00 10-Q · filed 2017-10-30 | ||
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $0.00 10-Q · filed 2017-07-28 | |||
| 2016-03-31 | $0.00 10-Q · filed 2017-04-28 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |